期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非小细胞肺癌EML4-ALK、EGFR的检测及临床病理特征的相关性研究 被引量：5

下载PDF
导出
摘要 目的探讨非小细胞肺癌(NSCLC)中抗表皮生长因子受体(EGFR)融合基因和棘皮动物微管查关蛋白样-4与间变性淋巴激酶融合基因(EML4-ALK)基因临床病理特征的相关性。方法应用即时荧光定量聚合酶链反应(PCR)法检测NSCLC中EML4-ALK、EGFR,并对其临床病理特征进行相关性分析。结果 160例NSCLC中60例(37.5%)存在EGFR基因突变,腺癌高于非腺癌;不吸烟患者高于吸烟患者;女性患者高于男性患者;差异均有统计学意义(均<0.05)。160例NSCLC中有7例EML4-ALK基因表达阳性,阳性表达率为4.4%(7/160)明显小于EGFR突变率,这7例阳性患者均为腺癌,其中6例主要细胞形态为腺泡样结构,5例伴有不同程度的细胞内或细胞外黏液。腺癌阳性率高于非腺癌;非吸烟患者高于吸烟患者;女性患者高于男性患者,但差异均无统计学意义(均>0.05)。结论 NSCLC患者中,EGFR及EML4-ALK阳性患者在临床病理上有一些相同或相似的特征,即女性、非吸烟、腺癌患者中较为多见,但也有一些不同的特征:EML4-ALK阳性患者中,腺癌中多伴有黏液产生的腺泡样结构,不同时合并EGFR突变。
作者 金夏祥 王旭州 陈兰 王爱忠
机构地区 中国人民解放军第 南京军区福州总医院
出处 《现代实用医学》 2014年第9期1067-1069,共3页 Modern Practical Medicine
关键词 肺癌 EGFR EML4-ALK 融合基因 病理
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1Jemal A, Siegel R, Ward E, et al. Cancer statistics[J]. CA Cancer J Clin, 2006, 56 (2): 106-130.
  • 2Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin paclitaxel in pul- monary adenocarcinoma[J]. N Engl J Med, 2009, 361(10): 947-957.
  • 3Zhou C, Wu YL, Chen G,et al. Erlotinib versus chemotherapy as first-line treat- ment for patients with advanced EGFRmutation positive non-small-cell lung can- aer: a multicemre, open-label,randomized, phase 3 study[J]. Lancet Oncol, 2011,12 (8): 735-742.
  • 4Soda M, Choi YL, Enomoto M, et al. Iden- tification of the transforming EML4-ALK fusion gene in non-small cell lung cancer[J]. Nature, 2007, 448(8): 561-566.
  • 5Horn L, Pao W. EML4-ALK: honing in on a new target in non-small cell lung can- cer[J]. J Clin Oncol, 2009, 27(26): 4232-4235.
  • 6张会娟,张晓彤,张力.EML4-ALK融合基因抑制剂耐药机制的研究进展[J].中华病理学杂志,2012,41(12):862-864. 被引量：5
  • 7Shaw AT, Yeap BY, Solomon B J, et al. Ef feet of crizotinib on overall survivalin pa- tients with advanced non-small cell lung cancer harbouring ALK gene rearrange- ment: a retrospective analysis[J]. Lancet Oncol, 2011, 12(11): 1004-1012.
  • 8钟山,张海萍,郑捷,白冬雨,付莉,陈培琼.非小细胞肺癌患者EML4-ALK融合基因检测及其与临床病理特征的关系[J].中华病理学杂志,2013,42(4):252-256. 被引量：19
  • 9韩卫,毕明宏.EML4-ALK融合基因在非小细胞肺癌中的临床意义[J].中国肺癌杂志,2013,16(2):97-101. 被引量：5
  • 10Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK- rearranged lung carcinomas[J]. Am J Surg Pathol, 2011,35(8): 1226-1234.

二级参考文献73

  • 1Ou SH. Crizotinib : a novel and first-in-class muhitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther, 2011,5 : 471-485.
  • 2Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non- small cell lung cancer. Clin Cancer Res, 2012,18 (5): 1472- 1482.
  • 3Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EMIA-ALK fusion gene in non-small-cell lung cancer. Nature, 2007,448(7153): 561-566.
  • 4Sasaki T, Rodig S J, Chirieac LR, et al. The biology and treatment of EMIA-ALK non-small cell lung cancer. Eur J Cancer, 2010,46(10) : 1773-1780.
  • 5Lin E, Li L, Guan Y, et al. Exon array profiling detects EMIA- ALK fusion in breast, colorecta|, and non-small cell lung cancers. Mol Cancer Res, 2009, 7 (9) : 1466-1476.
  • 6Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 2010, 363 (18) : 1693-1703.
  • 7Camidge DR, Bang YJ, Kwak EL, et al. Progression-free survival (PFS) from a phase 1 study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer ( NSCLC ). J Clin Oncol,2011,29(suppl) :abstr 2501.
  • 8Crino L, Kim D, Riely GJ, et al. Initial phase Ⅱ results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC) : PROFILE 1005. J Clin Oncol, 2011,29 (suppl) : abstr 7514.
  • 9Weickhardt A J, Rothman MS, Salian-Mehta S, et al. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer, 2012 [ Epub ahead of print].
  • 10Camidge DR, Doebele RC. Treating EML4-ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol, 2012,9 (5) :268-277.

共引文献31

同被引文献72

  • 1任学群,李宜雄,陈善正,胡国潢,应娇茜,李劲东,裴海平,陈志康,汤恢焕,吕新生.胰十二指肠切除术后胰瘘的危险因素[J].中国普通外科杂志,2006,15(10):772-776. 被引量：45
  • 2田宁,张侠,高文斌,等.非小细胞肺癌组织中EML4.ALK融合基因与ERCCl和RRMlmRNA表达的关系[J/CD].中华临床医师杂志:电子版,2013,7(22):9988-9922.
  • 3Shaw AT, Yeap BY, Solomon BJ, et a|. Effect of crizotinib on overall survival in patients with advanced non-small cell lungcancer harbouring ALK gene rearrangement: a retrospective analysis[J]. Lancet Oncol, 2011, 12( 11 ) : 1004 -1012.
  • 4MeLeer-Florin A, Moro-Sibilot D, Melis A, et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarc- inomas in a routine practic, e: a French study[J]. J Thorac Oncol, 2012, 7(2): 348-354.
  • 5Lin E, Li L, Guan Y, el al. Exon array profiling detects EM IA -ALK fusion in breast, coloreetal, and non-small cell lung cancers [J]. Mol Cancer Res, 2009, 7(9): 1446-1447.
  • 6Zhou C. Lung cancer molecular epidemiology in China: recent trends[J]. Transl Lung Cancer Res,2014,3 (5): 270-279.
  • 7Ryu JS, Memon A, Lee SK. ERCC 1 and personalized medicine in lung cance~J]. Ann Transl Med, 2014,2(4): 2305-2311.
  • 8Tang ER,Schreiner AM,Pua BB. Advances in lung ade- nocarcinoma classification: a summary of the new inter-national multidisciplinary classification system (IASLC/ ATS/ERS) [J~. J Thorac Dis,2014,6 (Suppl 5):$489- $501.
  • 9Liang W,Zhang L,Jiang G,et al. Development and vali- dation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer [J]. J Clin On- col, 2015,33 (8) : 861-869.
  • 10Mok TS,Wu YL,Thongprasert S, et al. Gefitinib or car- boplatin paclitaxel in pulmonary adenocarcinoma [J]. N Engl J Med, 2009,361(10) :947-957.

引证文献5

二级引证文献22

现代实用医学
2014年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部